Life-expectancy of patients enrolled in phase 1 clinical trials: A systematic review of published prognostic models

Critical Reviews in Oncology/Hematology

Volumn 83, Issue 2, 2012, Pages 242-248

  Ploquin, Anne ^a,b   Olmos, David ^c   Ferté, Charles ^b   Cassier, Philippe A ^c,d   Kramar, Andrew ^b   Duhamel, Alain ^a   Penel, Nicolas ^a,b  

^a UNIV LILLE   (France)

^b CENTRE OSCAR LAMBRET   (France)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Life expectancy; Phase 1 clinical trial; Prognostic Factors; Prognostic models; Survival

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; LACTATE DEHYDROGENASE; PACLITAXEL;

ALBUMIN BLOOD LEVEL; CANCER MORTALITY; HEMATOLOGIC MALIGNANCY; HUMAN; KARNOFSKY PERFORMANCE STATUS; LACTATE DEHYDROGENASE BLOOD LEVEL; LIFE EXPECTANCY; LUNG CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PREDICTION; PROGNOSIS; REVIEW; RISK FACTOR; SOLID TUMOR; SYSTEMATIC REVIEW; UNIVARIATE ANALYSIS;

CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; LIFE EXPECTANCY; MODELS, STATISTICAL; NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84864062082     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.11.008     Document Type: Review

References (25)

1. Craft B.S., Kurzrock R., Lei X., et al. The changing face of phase 1 cancer clinical trials. Cancer 2009, 115:1592-1597.
2. Verweij J. The prognosis of prognostic factors in phase I clinical trials. Ann Oncol 2000, 11:131-132.
3. Booth C.M., Calvert A.H., Giaccone G., Lobbezoo M.W., Seymour L.K., Eisenhauer E.A. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 2008, 44:19-24.
4. Morabito A., Di Maio M., De Maio E., Normanno N., Perrone F. Methodology of clinical trials with new molecular-targeted agents: where do we stand?. Ann Oncol 2006, 17(S7):vii128-vii131.
5. Parulekar W.R., Eisenhauer E.A. Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J of the Natl Cancer Inst 2004, 96:990-997.
6. Le Tourneau C., Faivre S., Raymond E., Diéras V. Méthodologie des essais de phase I en cancérologie. Bull Cancer 2007, 94:943-951.
7. Einsenhauer E.A., O'Dwyer P.J., Christian M., Humphrey J.S. Phase I clinical trial design in cancer drug development. J Clin Oncol 2000, 18:684-692.
8. Hunsberger S., Rubinstein L.V., Dancey J., Korn E.L. Dose escalation trial designs based on a molecularly targeted endpoint. Stat Med 2005, 24:2171-2181.
9. Dent S.F., Eisenhauer E.A. Phase I trial design: are new methodologies being put into practice?. Ann Oncol 1996, 7:561-566.
10. Arkenau H.T., Olmos D., Ang J.E., de Bono J., Judson I., Kaye S. Clinical outcome and prognosis factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience. Br J Cancer 2008, 98:1029-1033.
11. Janisch L., Mick R., Schilsky R.L., et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994, 74:1965-1973.
12. Italiano A., Massard C., Bahleda R., et al. Treatment outcome and survival in participants of phase 1 oncology trials carried out from 2003 to 2006 at Institute Gustave Roussy. Ann Oncol 2008, 19:787-792.
13. Han C., Braybrooke J.P., Deplanque G. Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents. Br J Cancer 2003, 89:1166-1171.
14. Kurzrock R., Benjamin R.S. Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med 2005, 352:930-932.
15. Roberts T.G., Goulard B.H., Squitieri L., et al. Trends in the risk and benefits to patients with cancer participating in phase 1 clinical trial. JAMA 2004, 292:2130-2140.
16. Horstmann E., McCabe M.S., Grochow L., et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med 2005, 352:895-904.
17. Yamamoto N., Tamura T., Fukuoka M., Saijo N. Survival and prognostic factors in lung cancer patients treated in phase I trials: Japanese experience. Int J Oncol 1999, 15:737-741.
18. Bachelot T., Ray-Coquard I., Catimel G., et al. Multivariate analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol 2000, 11:151-156.
19. Penel N., Vanseymortier M., Bonneterre M.E., et al. Prognostic factors among cancer patients with good performance status screened for phase I trials. Invest New Drugs 2008, 26:53-58.
20. Arkenau H.T., Olmos D., Ang J.E., et al. 90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?. Eur J Cancer 2008, 44:1536-1540.
21. Arkenau H.T., Barriuso J., Olmos D., et al. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials. J Clin Oncol 2009, 27:2692-2696.
22. Wheler J., Tsimberidou A.M., Hong D., et al. Survival of patients in a Phase 1 clinic: the M.D. Anderson Cancer Center expérience. Cancer 2009, 115:1091-1099.
23. Penel N., Delord J.P., Bonneterre M.E., et al. Development and validation of a model that predicts early death among cancer patients participating in phase 1 clinical trials investigating cytotoxics. Invest New Drugs 2010, 28:76-82.
24. Olmos D., A'Hern R., Marsoni S., et al. Multi-institutional prognostic factor analysis of patients enrolled in phase 1 oncology trials: can patients sélection be improved?. J Clin Oncol 2010, 28. [suppl; abstr 2518].
25. Hillman S.L., Mandrekar S.J., Bot B., et al. Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigation. J Clin Oncol 2010, 28:3002-3007.